Claudin-10 is a new candidate prognostic marker in metastatic high-grade serous carcinoma

被引：0
作者：
Ben Davidson
Delfim Doutel
Arild Holth
Dag Andre Nymoen
机构：
[1] Oslo University Hospital,Department of Pathology
[2] Norwegian Radium Hospital,Faculty of Medicine, Institute of Clinical Medicine
[3] University of Oslo,Department of Medical Genetics
[4] Instituto Português de Oncologia de Lisboa Francisco Gentil,undefined
[5] Serviço de Anatomia Patológica,undefined
[6] Oslo University Hospital,undefined
[7] Norwegian Radium Hospital,undefined
来源：
Virchows Archiv | 2023年 / 482卷
关键词：
Claudin-10; Quantitative RT-PCR; Immunohistochemistry; High-grade serous carcinoma; Mesothelioma; Effusion;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The objective of this study was to analyze the expression and prognostic role of the tight junction protein claudin-10 in high-grade serous carcinoma (HGSC). Claudin-10 protein expression by immunohistochemistry was analyzed in 588 HGSC (414 effusions, 174 surgical specimens). Expression in mesotheliomas (n = 97; 47 effusions, 50 surgical specimens) was studied for comparative purposes. CLDN10 mRNA expression by quantitative RT-PCR (qRT-PCR) was analyzed in 40 HGSC effusions. Claudin-10 protein expression was found in 360/588 (61%) HGSC vs. 19/97 (20%) mesotheliomas (p < 0.001), and was higher in HGSC surgical specimens compared to effusions (p < 0.001). qRT-PCR confirmed the presence of CLDN10 mRNA in HGSC effusions. High (> 25%) claudin-10 expression in HGSC effusions was significantly associated with shorter overall survival (OS; p = 0.036) and progression-free survival (PFS; p = 0.045) in univariate analysis, and was an independent prognosticator of OS in multivariate analysis (p = 0.045). In conclusion, claudin-10 protein expression is higher in HGSC compared to mesothelioma, although the diagnostic power of this marker appear to be lesser than other claudin family members. Claudin-10 expression in HGSC effusions is marker of more aggressive disease.
引用
收藏
页码：975 / 982
页数：7
相关论文
共 121 条
[1]  
Sung H(2021)Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries CA Cancer J Clin 71 209-249
[2]  
Ferlay J(2006)Claudins and epithelial paracellular transport Annu Rev Physiol 68 403-429
[3]  
Siegel RL(2006)The claudin gene family: expression in normal and neoplastic tissues BMC Cancer 6 186-5950
[4]  
Laversanne M(2006)Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma Clin Cancer Res 12 5944-254
[5]  
Soerjomataram I(2006)Claudins in differential diagnosis between mesothelioma and metastatic adenocarcinoma of the pleura J Clin Pathol 59 250-937
[6]  
Jemal A(2007)The diagnostic role of claudins in serous effusions Am J Clin Pathol 127 928-317
[7]  
Bray F(2011)Usefulness of Claudin 4 in the cytological diagnosis of serosal effusions Diagn Cytopathol 39 313-619
[8]  
Van Itallie CM(2014)Diagnostic value of claudin-4 marker in pleural and peritoneal effusion cytology: Does it differentiate between metastatic adenocarcinoma and reactive mesothelial cells? Adv Biomed Res 3 161-306
[9]  
Anderson JM(2019)Claudin-4 immunohistochemistry is a useful pan-carcinoma marker for serous effusion specimens Cytopathology 30 614-757
[10]  
Hewitt KJ(2014)Claudin-4 immunohistochemistry is highly effective in distinguishing adenocarcinoma from malignant mesothelioma in effusion cytology Cancer Cytopathol 122 299-3092
12345678910